Fusako Nishigaki

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.

Hirotsugu Ueda, Toshitaka Manda, Sanae Matsumoto et al. · The Journal of Antibiotics · 1994 · 255 citations

FK506 potently inhibits T cell activation induced TNF‐α and IL‐1β production <i>in vitro</i> by human peripheral blood mononuclear cells

Shozo Sakuma, Yasuko Kato, Fusako Nishigaki et al. · British Journal of Pharmacology · 2000 · 92 citations · Full text

Tumour Necrosis Factor, Immunology, Immune Regulation +23

Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.

Toshitaka Manda, Kyoichi Shimomura, Sueo Mukumoto et al. · PubMed · 1987 · 68 citations

Antitumor Activity, Chemoprevention Strategy, Apoptosis +16

Prevention of progressive joint destruction in collagen‐induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031

Takeshi Ishikawa, Fusako Nishigaki, Susumu Miyata et al. · British Journal of Pharmacology · 2004 · 62 citations · Full text

FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis

Shozo Sakuma, Fusako Nishigaki, Katsue Magari et al. · Inflammation Research · 2001 · 49 citations

Inflammation, Rheumatology, Rheumatoid Disorder +13